Prolactin, Inflammation, and Parkinson's Severity

This cross-sectional observational study aims to evaluate the relationship between serum prolactin levels, peripheral inflammatory markers (NLR, PLR, SII, CRP), and disease severity in patients with Parkinson's disease (PD). A total of at least 300 patients diagnosed with idiopathic PD will be included. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn-Yahr staging system. Serum and salivary prolactin levels will be measured using ELISA, while inflammatory markers will be calculated from routine blood tests. The study seeks to clarify whether prolactin and systemic inflammation indicators may serve as non-invasive biomarkers for disease progression and prognosis in PD, with particular emphasis on postmenopausal women.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Idiopathic Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Inflammation Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Prolactin Prolactin Levels Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Çanakkale Onsekiz Mart University

Çanakkale, Merkez, 17020, Turkey (Türkiye)

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years
Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist
Both male and postmenopausal female patients
Patients able to provide informed consent
Clinically stable enough to undergo blood and saliva sampling, as well as neurological assessment

Exclusion criteria

Premenopausal female patients
Patients with secondary or atypical parkinsonism (e.g., drug-induced, vascular, atypical parkinsonian syndromes)
Known endocrine disorders affecting prolactin levels (e.g., prolactinoma, pituitary adenoma, hypothyroidism)
Use of medications known to alter prolactin secretion (e.g., antipsychotics, dopamine antagonists, estrogen therapy)
History of other neurodegenerative diseases (e.g., Alzheimer's, Huntington's)
Presence of active infection, chronic inflammatory disease, or malignancy
Severe renal, hepatic, or cardiac failure
Inability to provide informed consent

Treatment and study plan

Primary outcomes

Systemic inflammatory markers

Time frame: 1 year later

NLR, PLR, SII, CRP
Prolactin Level

Time frame: 1 year later

Serum prolactine levels

Sponsors and collaborators

Lead sponsor

Çanakkale Onsekiz Mart University

Other

Registry information

Official study title

The Relationship of Prolactin and Inflammatory Markers With Parkinson's Disease Severity: Clinical and Biochemical Evaluation

Acronym: PRIPS

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2026
First posted: Sep 9, 2025
Registry last updated: Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting